




Synthesis of ATP-antagonist inhibitors of CDK2

Student: **Biagio Palmisano**

Relator: **Prof. Rino Ragno**

Supervisor: **Prof. Gilbert Kirsch**

Academic Year: 2012/2013



by www.RCND.it




UNIVERSITÉ
DE LORRAINE

Laboratoire d'Ingénierie Moléculaire
LIMBP
et Biochimie Pharmacologique




HARMONIC
PHARMA
ADDING THERAPEUTIC VALUE




Introduction

by www.RCND.it

The role of CDK2







Introduction


by www.RCND.it

Why inhibitors?


CDK2
ACTIVE
SITE



A





B



Synthetic scheme for molecule A


[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine







Synthetic scheme for molecule B


4-[(4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl)amino] benzenesulfonamide







3-chloropenta-2,4-dione formation







1-(2-amino-4-methylthiazol-5-yl)ethanone formation







N'-[5-(3-Dimethylaminoacryloyl)-4-methylthiazol-2-yl]-N,N-dimethylformamide formation






3-nitrophenylguanidine nitrate formation






[4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine formation





B= $\text{CH}_3\text{OCH}_2\text{CH}_2$


7

O₂N



2-bromoacetoacetaldehyde formation







Mechanisms

by www.RCND.it

1-(imidazo[1,2-a]pyridin-3-yl)ethanone formation









Thanks for Your attention!



SAPIENZA
UNIVERSITÀ DI ROMA